Nonradioactive Serum Digoxin and Digitoxin Levels

Shapiro, William

doi:10.1001/archinte.1972.03650010019004

Cited by 13 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Digitoxin is a well-known cardiac glycoside [ 9 , 10 , 11 ] with the potential to act as a potent anti-cancer drug in the therapeutic concentration range of 25–40 nM [ 10 , 12 , 13 ]. Epidemiological data suggest that patients who received treatment with the cardiac glycosides digoxin or digitoxin have a higher survival rate and lower recurrence in different cancer malignancies [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Digitoxin Affects Metabolism, ROS Production and Proliferation in Pancreatic Cancer Cells Differently Depending on the Cell Phenotype

Lindholm

Ejeskär

Szekeres

2022

IJMS

View full text Add to dashboard Cite

Digitoxin has repeatedly shown to have negative effects on cancer cell viability; however, the actual mechanism is still unknown. In this study, we investigated the effects of digitoxin (1–100 nM) in four pancreatic cancer cell lines, BxPC-3, CFPAC-1, Panc-1, and AsPC-1. The cell lines differ in their KRAS/BRAF mutational status and primary tumor or metastasis origin. We could detect differences in the basal rates of cell proliferation, glycolysis, and ROS production, giving the cell lines different phenotypes. Digitoxin treatment induced apoptosis in all four cell lines, but to different degrees. Cells derived from primary tumors (Panc-1 and BxPC-3) were highly proliferating with a high proportion of cells in the S/G2 phase, and were more sensitive to digitoxin treatment than the cell lines derived from metastases (CFPAC-1 and AsPC-1), with a high proportion of cells in G0/G1. In addition, the effects of digitoxin on the rate of glycolysis, ROS production, and proliferation were dependent on the basal metabolism and origin of the cells. The KRAS downstream signaling pathways were not altered by digitoxin treatment, thus the effects exerted by digitoxin were probably disconnected from these signaling pathways. We conclude that digitoxin is a promising treatment in highly proliferating pancreatic tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Digitoxin Affects Metabolism, ROS Production and Proliferation in Pancreatic Cancer Cells Differently Depending on the Cell Phenotype

Lindholm

Ejeskär

Szekeres

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Measurement of SDC has been reported since the late 1960s. 9) The package insert of digoxin and guidelines recommend TDM for digoxin. 3,4,10) Studies from Japan and the United States (US) indicated that TDM was performed in 17−50% of patients receiving digoxin.…”

Section: Introductionmentioning

confidence: 99%

Frequency of Clinical Monitoring of Serum Concentrations of Digoxin, Potassium, and Creatinine, and Recording of Electrocardiograms in Digoxin-Treated Patients: A Japanese Claims Database Analysis

Ooba

Sente

Abe

et al. 2020

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Guidelines for cardiovascular drug therapy recommend monitoring serum digoxin concentration (SDC) in patients receiving digoxin treatment, especially those with renal dysfunction and hypokalemia. However, only a few studies have reported the prevalence of SDC monitoring and laboratory testing in clinical practice. Therefore, the aim of this study was to describe the frequency of SDC monitoring and laboratory testing in digoxin users and to assess the association between SDC monitoring and patient characteristics. We used the Japanese insurance claims data covering approximately 1.7 million patients aged 20−74 years between January 1, 2005 and March 31, 2014. All patients who had at least one prescription for digoxin were included. The frequency of SDC and laboratory tests was calculated and the association between patient characteristics and SDC monitoring was assessed using logistic regression analysis. A total of 98,867 prescriptions of digoxin were issued to 3,458 patients between 2005 and 2014. The annual mean frequencies of monitoring SDC, serum potassium level and serum creatinine level and of recording electrocardiograms was 16.8%, 34.8%, and 38.7% and 24.1%, respectively. Atrial fibrillation, chronic heart failure, renal diseases, and use of oral anticoagulants were associated with SDC monitoring. We found the frequency of SDC monitoring to be relatively low in Japanese clinical practice.

show abstract

Influence of Cardiac Glycosides on Electrolyte Exchange and Content in Cardiac Muscle Cells

Nayler¹,

Noack²

1981

Cardiac Glycosides

View full text Add to dashboard Cite

Nonradioactive Serum Digoxin and Digitoxin Levels

Cited by 13 publications

References 13 publications

Digitoxin Affects Metabolism, ROS Production and Proliferation in Pancreatic Cancer Cells Differently Depending on the Cell Phenotype

Digitoxin Affects Metabolism, ROS Production and Proliferation in Pancreatic Cancer Cells Differently Depending on the Cell Phenotype

Frequency of Clinical Monitoring of Serum Concentrations of Digoxin, Potassium, and Creatinine, and Recording of Electrocardiograms in Digoxin-Treated Patients: A Japanese Claims Database Analysis

Influence of Cardiac Glycosides on Electrolyte Exchange and Content in Cardiac Muscle Cells

Contact Info

Product

Resources

About